Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
UBS lifts H World, Wells Fargo reprises Netflix coverage, and JD.com shares a reduced target as institutional views s...
Grocery Outlet faces supply-chain and affordability pressures, while Scholastic gauges upside; analysts adjust target...
RBC Capital Markets upgrades Dow Inc. and LyondellBasell to Outperform, citing Iran-related supply squeezes in global...
Top U.S. homebuilders are backing Avila Real Estate Capital’s AREC Fund II, signaling a shift in housing finance as b...
Two March data drops could tease the next cost-of-living adjustment for social security retirees, even though the off...
In 2026, the global air fleet is being renewed around a handful of high-performance fighters. Investors are watching ...
Tensions over Iran have flipped XRP into a geopolitics-driven asset. As the Iran conflict escalates, traders watch pr...
Samsung and Apple tied on annual smartphone production in TrendForce’s data, sparking fresh market debate on leadersh...
Netflix walks away from an $83 billion Warner Bros. deal, freeing capital for expansion and content, lifting the stoc...
A veteran strategist warns that the odds stock market meltdown could jump to 35% this year as oil shocks and sluggish...